Multivariate analysis of differential lymphocyte cell cycle activity in Alzheimer's disease

Neurobiology of Aging

Volumn 33, Issue 2, 2012, Pages 234-241

  Stieler, Jens ^a   Grimes, Randy ^b   Weber, Don ^b   Gartner, William ^b   Sabbagh, Marwan ^b,c   Arendt, Thomas ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b ProvistaLife Sciences LLC   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Biomarker; Cell cycle activation; Dementia; Diagnosis; Parkinson's disease dementia; Peripheral blood lymphocytes

Indexed keywords

BIOLOGICAL MARKER; CD28 ANTIGEN; CD68 ANTIGEN;

AGED; ALZHEIMER DISEASE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL ACTIVITY; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEMENTIA; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIVARIATE ANALYSIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; T LYMPHOCYTE; UNIVARIATE ANALYSIS;

AGED; ALZHEIMER DISEASE; CELL CYCLE; CELL CYCLE PROTEINS; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MULTIVARIATE ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 82755191611     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.03.001     Document Type: Article

References (42)

1. Andreasen N., Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin. Neurol. Neurosurg 2005, 107:165-173.
2. Arendt T. Differentiation and de-differenntiation - Neuronal cell cycle regulation during development and age-related neurodegenerative disorders. Handbook of Neurochemistry and Molecular Neurobiology 2008, 160-197. Springer. A. Lajtha (Ed.).
3. Arendt T., Rödel L., Gärtner U., Holzer M. Expression of the cyclin dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport 1996, 7:3047-3049.
4. Bonotis K., Krikki E., Holeva V., Aggouridaki C., Costa V., Baloyannis S. Systemic immune aberrations in Alzheimer's disease patients. J. Neuroimmunol 2008, 193:183-187.
5. Bossù P., Ciaramella A., Salani F., Bizzoni F., Varsi E., Di Iulio F., Giubilei F., Gianni W., Trequattrini A., Moro M.L., Bernardini S., Caltagirone C., Spalletta G. Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment. Brain Behav. Immun 2008, 22:487-492.
6. Busser J., Geldmacher D.S., Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J. Neurosci 1998, 18:2801-2807.
7. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 1998, 19:109-116. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease,".
8. Cummings J.L., Donohue J.A., Brooks R.L. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am. J. Geriatr. Psychiatry 2000, 8:134-140.
9. DeKosky S. Early intervention is key to successful management of Alzheimer disease. Alzheimer Dis. Assoc. Disord 2003, 17.
10. Emiliani C., Urbanelli L., Racanicchi L., Orlacchio A., Pelicci G., Sorbi S., Bernardi G., Orlacchio A. Up-regulation of glycohydrolases in Alzheimer's Disease fibroblasts correlates with Ras activation. J. Biol. Chem 2003, 278:38453-38460.
11. Frank R.A., Galasko D., Hampel H., Hardy J., de Leon M.J., Mehta P.D., Rogers J., Siemers E., Trojanowski J.Q. Biological markers for therapeutic trials in Alzheimer's disease. In Proceedings of the Biological Markers Working Group; NIA Initiative on Neuroimaging in Alzheimer's Disease. Neurobiol. Aging 2003, 24:521-536.
12. Gatta L., Cardinale A., Wannenes F., Consoli C., Armani A., Molinari F., Mammi C., Stocchi F., Torti M., Rosano G.M., Fini M. Peripheral blood mononuclear cells from mild cognitive impairment patients show deregulation of Bax and Sod1 mRNAs. Neurosci. Lett 2009, 453:36-40.
13. Gladkevich A., Kauffman H.F., Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:559-576.
14. Hirashima N., Etcheberrigaray R., Bergamaschi S., Racchi M., Battaini F., Binetti G., Govoni S., Alkon D.L. Calcium responses in human fibroblasts: a diagnostic molecular profile for Alzheimer's disease. Neurobiol. Aging 1996, 17:549-555.
15. Honig L.S., Schupf N., Lee J.H., Tang M.X., Mayeux R. Shorter telomeres are associated with mortality in those with APOE epsilon4 and dementia. Ann. Neurol 2006, 60:181-187.
16. Ikeda T., Yamamoto K., Takahashi K., Yamada M. Immune system-associated antigens on the surface of peripheral blood lymphocytes in patients with Alzheimer's disease. Acta Psychiatr. Scand 1991, 83:444-448.
17. Inestrosa N.C., Alarcon R., Arriagada J., Donoso A., Alvarez J., Campos E.O. Blood markers in Alzheimer disease: subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes. J. Neurol. Sci 1994, 122:1-5.
18. Jenkins E.C., Velinov M.T., Ye L., Gu H., Li S., Jenkins E.C., Brooks S.S., Pang D., Devenny D.A., Zigman W.B., Schupf N., Silverman W.P. Telomere shortening in T lymphocytes of older individuals with Down syndrome and dementia. Neurobiol. Aging 2006, 27:941-945.
19. Kassner S.S., Bonaterra G.A., Kaiser E., Hildebrandt W., Metz J., Schröder J., Kinscherf R. Novel systemic markers for patients with Alzheimer disease? - a pilot study. Curr. Alzheimer Res 2008, 5:358-366.
20. + monocyte/macrophages in patients with Alzheimer's disease. Immunobiology 2000, 202:26-33.
21. Larbi A., Pawelec G., Witkowski J.M., Schipper H.M., Derhovanessian E., Goldeck D., Fulop T. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J. Alzheimers Dis 2009, 17:91-103.
22. Lombardi V.R., Garcia M., Rey L., Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J. Neuroimmunol 1999, 97:163-171.
23. Maccioni R.B., Lavados M., Maccioni C.B., Mendoza-Naranjo A. Biological markers of Alzheimer's disease and mild cognitive impairment. Curr. Alzheimer Res 2004, 1:307-314.
24. Maes O.C., Xu S., Yu B., Chertkow H.M., Wang E., Schipper H.M. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol. Aging 2007, 28:1795-1809.
25. Magaki S., Yellon S.M., Mueller C., Kirsch W.M. Immunophenotypes in the circulation of patients with mild cognitive impairment. J. Psychiatr. Res 2008, 42:240-246.
26. Mayeux R., Saunders A.M., Shea S., Mirra S., Evans D., Roses A.D., Hyman B.T., Crain B., Tang M.X., Phelps C.H. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N. Engl. J. Med 1998, 338:506-511.
27. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
28. Mendez M.F., Mastri A.R., Sung J.H., Frey W.H. Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases. Alzheimer Dis. Assoc. Disord 1992, 6:35-43.
29. Nagy Z., Esiri M.M., Cato A.M., Smith A.D. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol 1997, 94:6-15.
30. Panossian L.A., Porter V.R., Valenzuela H.F., Zhu X., Reback E., Masterman D., Cummings J.L., Effros R.B. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol. Aging 2003, 24:77-84.
31. Payan D.G., McGillis J.P., Goetzl E.J. Neuroimmunology. Adv. Immunol 1986, 39:299-323.
32. Pirttila T., Mattinen S., Frey H. The decrease of CD8-positive lymphocytes in Alzheimer's disease. J. Neurol. Sci 1992, 107:160-165.
33. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med 2007, 13:1359-1362.
34. Reale M., Greig N.H., Kamal M.A. Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini Rev. Med. Chem 2009, 9:1229-1241.
35. Reale M., Iarlori C., Feliciani C., Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J. Alzheimers Dis 2008, 14:147-159.
36. Shalit F., Sredni B., Brodie C., Kott E., Huberman M. lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. Clin. Immunol. Immunopathol 1995, 75:246-250.
37. Stieler J.T., Lederer C., Brückner M.K.Wolf.H., Holzer M., Gertz H.J., Arendt T. Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease. Neuroreport 2001, 12:3969-3972.
38. + T cells as a potential diagnostic marker of Alzheimer's disease. J. Neuroimmunol 2002, 132:164-172.
39. Tierney M.C., Fisher R.H., Lewis A.J., Zorzitto M.L., Snow W.G., Reid D.W., Nieuwstraten P. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 1988, 38:359-364.
40. Varma A.R., Snowden J.S., Lloyd J.J., Talbot P.R., Mann D.M., Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 1999, 66:184-188.
41. Vincent I., Rosado M., Davies P. Mitotic mechanisms in Alzheimer's disease?. J. Cell Biol 1996, 132:413-415.
42. Zhang J., Kong Q., Zhang Z., Ge P.D., He W. Telomere dysfunction of lymphocytes in patients with Alzheimer disease. Cogn. Behav. Neurol 2003, 16:170-176.